Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 1 (BBTIMV1)
Treatment of Insomnia in Military Veterans:Phase 1
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Western Psychiatric Institute and Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age is 18 and older.
- Military returnees from OIF/OEF
Meet diagnostic criteria for chronic insomnia as defined by:
- a. Complaint of sleep latency >30 minutes, or wake time after sleep onset >30 minutes, or Sleep Efficiency <85%, or a complaint of non-restorative sleep;
- b. Frequency of insomnia complaint >3 times per week;
- c. Duration of insomnia complaint >1 month
- d. Associated with at least one daytime consequences
- If using sleep medications, medication and dosage have not been changed in the past month, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
- If using other psychotropic medications, medication and dosage have not been changed in the past 2 months, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
Exclusion Criteria:
- Active duty personnel, or reservists/national guards scheduled for re-deployment over the following eight months
- Untreated, current, and severe PTSD as determined on the SCID.
- Untreated, current, and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory
- Psychotic or bipolar disorder
- Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results
- Unstable medical condition
- Hospitalization in the previous 2 weeks for a medical condition or surgery for which recovery overlaps with the study onset and duration
- Seizure disorder or traumatic brain injury.
- Current sleep disorders such as nightmare disorder, restless legs syndrome, or suspected sleep disorder requiring polysomnographic assessment, such as obstructive sleep apnea or periodic leg movements.
- Sleep apnea revealed during the screening sleep study.
- Pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Brief Behavioral Treatment for Insomnia
|
Effective behavioral insomnia treatments are typically delivered over an 8-week period.
This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help.
The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pittsburgh Sleep Diary
Time Frame: Weekly during entire participation
|
Weekly during entire participation
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline and Post Intervention
|
Baseline and Post Intervention
|
|
PSQI Addendum for PTSD (PSQIA)
Time Frame: Baseline and Post Intervention
|
Baseline and Post Intervention
|
|
Sleep quality defined by:PIRS 20 and the ISI
Time Frame: Screening, Baseline, and Post Intervention
|
Screening, Baseline, and Post Intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PTSD symptom severity as measured by the CAPS
Time Frame: Screening
|
Screening
|
|
Depression: BDI
Time Frame: Baseline and Post Intervention
|
Baseline and Post Intervention
|
|
Anxiety: BAI
Time Frame: Baseline and Post Intervention
|
Baseline and Post Intervention
|
|
Medical History: MHQ, MEDHIST_2WK, MOS
Time Frame: Screening, Baseline, and Post Intervention
|
Screening, Baseline, and Post Intervention
|
|
Trauma History: THQ,CES,PCL-C,ICG
Time Frame: Screening, Baseline, and Post Intervention
|
Screening, Baseline, and Post Intervention
|
|
Post Sleep Self Report: PSEQ-SV and POST
Time Frame: Screening
|
Screening
|
|
Sleepiness: EPWORTH, BASS
Time Frame: Screening, Baseline, and Post Intervention
|
Screening, Baseline, and Post Intervention
|
|
Expectations and Satisfaction: TEQ-94, Client Satisfaction Survey
Time Frame: Baseline and Post Intervention
|
Baseline and Post Intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Anne Germain, PhD., University of Pittsburgh, Department of Psychiatry
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO07110063
- NIMH: 1 R34 MH080696
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.